Astraveus SAS is pleased to announce the appointment of Michel Spagnol as the new Chairman of its Board. Joining existing Board members Jérémie Laurent (CEO), Alain Huriez (Director), AdBio Partners, Christian Ulrich (Director, M Ventures), Fiona MacLaughlin (Director, JJDC), and Laurent Higueret (Director, BPI France Large Venture).
Michel, a Stanford PhD graduate, brings a wealth of experience and expertise to Astraveus. With over 30 years of international experience in the healthcare industry, Michel has demonstrated his ability to successfully lead the transformation of multiple advanced technologies into both industrial and commercial successes. Formerly the CEO and Chairman of Novasep, an international CDMO group based in France (now part of the Axplora group), Michel led the restructuring of the Novasep group, significantly increasing its value to €1.5 billion. During his tenure, he expanded its gene therapy franchise into a globally recognized CDMO, ultimately leading to its divestment to Thermos Fisher Scientific group in 2021, providing him with extensive knowledge of Astraveus' target market. Prior to this role, he held leadership positions at Rhodia Pharma Solutions and Shasun. Currently serving as Deputy Chairman at Axplora group, Michel is also a Board member and Chairman of the SAB at MVG Group. Additionally, he is the Founder and President of Mifani-Invest, a venture focused on healthcare and digital transformation investments.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!